{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'medical background, a modification of study entry', 'rescreened 1 time if there is a change in the status of', 'criteria, or other relevant change.status of the patient', 'the patient regarding eligibility for the study.', 'regarding eligibility for the study.', 'The screening visit will take place not more than 31', 'The screening visit will take place not more than 31', 'days before the baseline visit. The screening visit', 'days before the baseline visit. The screening visit', 'may be conducted over 2 separate visits at the', 'may be conducted over 2 separate visits at the', 'discretion of the investigator. The following', 'discretion of the investigator. The following', 'procedures will be performed at screening:', 'procedures will be performed at screening:', 'conduct clinic visit', 'conduct clinic visit', 'Section 4.1. Patient Inclusion Criteria (other section affected: Section 12.1 Informed Consent/Assent)', 'f. Patient and caregiver/adult (may also include an', 'f.', 'Patient and caregiver/adult are willing to adhere', 'Updated language surrounding', 'adult other than a parent or legal representative) are', 'to the medication regimen and to comply with all', 'who can be involved in the', 'willing to adhere to the medication regimen and to', 'study procedures.', 'informed consent/assent process.', 'comply with all study procedures.', \"h. In the investigator's opinion, the patient and\", 'Removed a parenthetical', \"h. In the investigator's opinion, the patient and\", 'caregiver/adult have the ability to understand the', 'expression that was inserted', 'caregiver/adult (may also include an adult other than', 'nature of the study and its procedures, and the patient', 'previously', 'parent or logal representative) have the ability to', 'is expected to complete the study as designed.', 'understand the nature of the study and its procedures,', 'i.', 'Patient and caregiver/adult provide written', 'and the patient is expected to complete the study as', \"informed consent/assent, depending on the child's\", 'designed.', 'age, as appropriate, according to local regulations.', 'i.', 'Patient and caregiver/adult (may also include an', 'adult other than a parent or legal representative)', 'provide written informed consent/assent, depending', \"on the child's age, as appropriate, according to local\", 'regulations.', 'Section 4.4 Withdrawal Criteria and Procedures (other section affected: Section 7.1.7 Withdrawal Due to an Adverse', 'Event)', 'b. adverse events (any patient who experiences an', 'b. adverse events (any patient who experiences an', 'Included clarity that patients who', 'adverse event may be withdrawn from the study or', 'adverse event may be withdrawn from the study or', 'experience an adverse event can', 'from study treatment at any time at the discretion of', 'from study treatment at any time at the discretion of', 'also be withdrawn by the sponsor.', 'the investigator or sponsor as indicated in Section', 'the investigator or sponsor as indicated in Section', 'Provided further guidance to the', '201']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', '7.1.7)', '7.1.7)', 'investigator in the situation that a', 'g. when a blind is broken due to safety concerns', 'g. when a blind is broken due to safety concerns', 'patient is unblinded by mistake', '(see Section 3.7.2). If a patient is unblinded by', '(see Section 3.7.2). If a patient is unblinded by', 'mistake, theythe investigator should discuss with the', 'mistake, the investigator should discuss with the', 'medical monitor whether or not the patient should be', 'medical monitor whether or not the patient should be', 'withdrawn.', 'withdrawn.', 'Section 5.5 Dose Reduction and Temporary IMP Discontinuation', 'Dose Suspension', 'Dose Suspension', 'Updated dose suspension text to', \"If a subject's serum potassium or magnesium were\", \"If a subject's serum potassium or magnesium were\", 'provide further guidance', 'tested and found to be below the lower limit of', 'tested and found to be below the lower limit of', 'normal, IMP must be suspended and clinically', 'normal and clinically significant, the laboratory test', 'significant, the laboratory test should be repeated at', 'should be repeated at least once. If the abnormality in', 'least once. If the abnormality in the repeated', 'the repeated laboratory test is consistent with the', 'laboratory test is consistent with the prior laboratory', 'prior laboratory test, the IMP must be suspended.', 'test, the IMP must be suspended.', 'Section 6.2.5 Yale Global Tic Severity Scale', 'are', 'Updated to more properly capture', 'exploratory measures.', 'the YGTSS measures', 're exploratory', 'measures.', 'Section 7.11 Concomitant Therapy or Medication', 'Medications that are allowed, provided that', 'Medications that are allowed, provided that', 'Updated allowed medications to', 'conditions outlined in the table are met, are shown in', 'conditions outlined in the table are met, are shown in', 'clarify that the list of concomitant', 'Appendix A, Table 9. The tables of allowed and', 'Appendix A, Table 9. The tables of allowed and', 'medications provided is not', 'prohibited medications are not comprehensive and', 'prohibited medications are not comprehensive and', 'comprehensive', 'may not include all possible concomitant', 'may not include all possible concomitant', 'medications.', 'medications.', 'Section 9.1 Sample Size and Power Considerations (other section affected: Figure 1: Overall Study Schema)', 'It is estimated that approximately 5058 patients per', 'It is estimated that approximately 58 patients per arm', 'Recently, a Phase 2 study', 'arm will enable a power of at least 90% to detect a', 'will enable a power of at least 90% to detect a', 'assessing the safety and efficacy', 'beneficial standardized effect of 6.5 points63\u00b0 or', 'beneficial standardized effect of 63% or more when', 'of valbenazine in the treatment of', '202']\n\n###\n\n", "completion": "END"}